{"id":3961,"date":"2026-10-28T09:00:00","date_gmt":"2026-10-28T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3961"},"modified":"2026-10-28T20:49:39","modified_gmt":"2026-10-29T00:49:39","slug":"geron-stops-impactmf-after-survival-futility-review","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3961","title":{"rendered":"Geron Stops IMpactMF After Survival Futility Review"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Geron<\/p>\n

Event Type<\/strong><\/p>\n

Phase 3 discontinuation (futility)<\/p>\n

Modality<\/strong><\/p>\n

Telomerase-inhibiting oligonucleotide<\/p>\n

Asset<\/strong><\/p>\n

Imetelstat (IMpactMF)<\/p>\n

Target<\/strong><\/p>\n

Telomerase<\/p>\n

Disease Area<\/strong><\/p>\n

JAK-inhibitor relapsed\/refractory myelofibrosis<\/p>\n

Summary<\/h4>\n

On 28 October Geron discontinued the 327-patient Phase III IMpactMF trial after its independent monitoring committee judged an overall-survival benefit unlikely in JAK-inhibitor relapsed or refractory myelofibrosis. This is a negative program signal, while the full dataset remains undisclosed.<\/p>\n

The open-label 2:1 randomized study compared intravenous imetelstat 9.4 mg\/kg every three weeks with best available therapy in intermediate-2 or high-risk disease. The company said no new safety signal changed known monitoring requirements. It has not reported the futility boundary, hazard ratio, event count, subgroup results or complete toxicity profile. Imetelstat remains approved for specified lower-risk MDS populations in the United States and European Union; that is a distinct indication.<\/p>\n

Deep Analysis<\/h4>\n

The endpoint was survival, a high-value test of disease modification after JAK inhibitors. A monitoring recommendation makes a clinically meaningful OS advantage at the planned analysis improbable, but does not establish zero antitumor activity or a specific mechanism of failure. Open-label best-available-therapy control may affect ancillary outcomes, though death is less susceptible to assessment bias. A telomerase inhibitor can plausibly affect malignant progenitors without delivering sufficient late-line survival benefit; exposure, cytopenias, crossover and subsequent therapies require full analysis. No efficacy inference should be imported from lower-risk MDS.<\/p>\n

Company and Product Background<\/h4>\n

Myelofibrosis is a clonal marrow disease with fibrosis, cytopenias and splenomegaly. Imetelstat is an oligonucleotide telomerase inhibitor intended to suppress malignant hematopoietic clones.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> imetelstat lacks sufficient survival effect in this population; DMC futility supports that.<\/li>\n
  • Interpretation B:<\/strong> patient mix, dose intensity or competing deaths masked biologic activity; possible but unsupported without data.<\/li>\n
  • Upgrade<\/strong> any salvage thesis with prespecified subgroup and biomarker results plus durable symptom or spleen benefit. Downgrade<\/strong> it if mature OS and quality-of-life data are consistently neutral. A replicated randomized survival benefit would falsify<\/strong> the current negative program interpretation.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: the Phase III myelofibrosis expansion path has materially narrowed. The decision does not alter the separate approved MDS claim.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: negative for the myelofibrosis program. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    On 28 October Geron discontinued the 327-patient Phase III IMpactMF trial after its independent monitoring committee judged an overall-survival benefit unlikely in JAK-inhibitor relapsed or refractory myelofibrosis. This is a negative program signal, while…<\/p>\n","protected":false},"author":1,"featured_media":3972,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1268,1266,1267,60,1107],"class_list":["post-3961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-futility","tag-geron","tag-imetelstat","tag-myelofibrosis","tag-phase-3"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3961"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3961\/revisions"}],"predecessor-version":[{"id":3977,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3961\/revisions\/3977"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3972"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}